



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BGT226

Chemical Properties

CAS No. :	915020-55-2
Formula:	C ₂₈ H ₂₅ F ₃ N ₆ O ₂
Molecular Weight:	534.53
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	BGT226 (NVP-BGT226) is a novel dual PI3K / mTOR inhibitor, it acts on PI3K $\alpha/\beta/\gamma$ with IC ₅₀ of 4 nM / 63 nM / 38 nM, respectively.
Targets(IC ₅₀)	PI3K,mTOR,Autophagy
In vitro	Growth inhibition experiment showed that BGT226 had antitumor activity. BGT226 significantly inhibited cell growth with IC ₅₀ < 20 nM. BGT226 also induced cancer cell apoptosis at nanomolar concentration, IC ₅₀ ≤ 25 nM[1][2][3].
In vivo	BGT226 significantly delayed tumor growth on the transplanted tumor animal model. This effect was dose-dependent, accompanied by inhibition of p-p70 S6 kinase cytoplasmic expression and autophagy body formation[2].

Solubility Information

Solubility	DMSO: 65 mg/ml (121.6 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8708 mL	9.354 mL	18.708 mL
5 mM	0.3742 mL	1.8708 mL	3.7416 mL
10 mM	0.1871 mL	0.9354 mL	1.8708 mL
50 mM	0.0374 mL	0.1871 mL	0.3742 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Markman B , Tabernero J , Krop I , et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors[J]. Annals of

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481